SARS-CoV-2 Nucleocapsid protein – 1.0 mg

85,00 excl. Vat

Categories: ,

SARS-CoV-2 Nucleocapsid protein – 1.0 mg
PRODUCT CODE: X-PRO-0006-1.0MG
ALIQUOTING: 1 X 1.0 mg vial
STORAGE: < -18 °C

PRODUCT DESCRIPTION
The nucleocapsid protein (N-protein) is the most abundant protein in SARS-CoV-2 coronavirus. The association of nucleocapsid protein with single-stranded viral RNA leads to the formation of the helical nucleocapsid structure. The nucleocapsid protein is highly immunogenic and is often used as a marker in diagnostic assays. About a week after SARS onset, nucleocapsid specific antibodies may be detected and sustain for long time. For convenient amino-based conjugation, the product is free from amino-based puffers.

PRECAUTIONS AND DISCLAIMER
This product is for LABORATORY RESEARCH USE ONLY, not for diagnostic, therapeutic, drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

FORMULATION
For shipping at ambient temperature the protein is liquid-stabilized with a HEPES, NaCl, small molecule buffer base at neutral pH.

PREPARATION AND HANDLING
Stock solutions can be diluted in appropriate buffers.

STORAGE / STABILITY
For long term storage the liquid-stabilized protein should be stored below – 18 °C. Repeated freeze-thaw cycles (> 5) should be avoided. For long term usage, stock solutions can be frozen in working aliquots.

CHARACTERISTICS
The E. coli expressed recombinant SARS-CoV-2 Nucleocapsid Protein has a molecular mass of 47 kDa and a predicted isoelectric point of 10.

RECOMMENDED DILUTION
For protein conjugation a final concentration of 0.2 to 1 mg/ml is recommended. For direct microplate coating a final concentration of 0.5 to 5 μg/ml is recommended. For optimal performance the reagent should be titrated for each application.

BACKGROUND REFERENCES
1. Zeng W., et al., Biochemical Characterization of SARS-CoV-2 Nucleocapsid Protein, Biochem Biophys Res Commun, 527(3): 618-623 (2020). 

2. Muriaux D., et al. Properties and functions of the nucleocapsid protein in virus).


BioThinx warrants, that at the time of the quality release or subsequent retest date this product conformed to the information contained in this publication. Purchaser must determine the suitability of the product(s) for its particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip. No other warranties, express or implied, are granted, including without limitation, implied warranties of merchantability, fitness for any particular purpose, or non-infringement

 


EXAMPLE
Antigen coated microplate detection of anti- SARS-CoV-2 Nucleocapsid human antibodies in COVID-19 serum samples (01-06 COV2) and healthy blood donors (01-06 BD).

Sample

SARS-CoV-2 Nucleocapsid lgG OD [450 nm]

SARS-CoV-2 Nucleocapsid lgM OD [450 nm]

01-COV2

1,63

1,35

02-COV2

1,39

0,24

03-COV2

2,9

0,8

04-COV2

3,58

3,29

05-COV2

3,57

1,66

06-COV2

>4

1,01

01-BID

0,10

0,23

02-BID

0,13

0,13

03-BID

0,13

0,15

04-BID

0,12

0,20

05-BID

0,21

0,15

06-BID

0,14

0,23